Studying Early Lung Cancer Types Using Multi-Omics Analysis
Compares genes and biology of early lung cancers in adults after surgery.
Key facts
- Who runs it
- Central South University
- Where
- Changsha, ChinaSee the site
- Trial code
- Registry title
- Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 29 Aug 2024
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Record updated
- 7 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with early-stage non-small cell lung cancer who have multiple primary lung cancers or lung cancer next to cystic airspaces seen on CT.
- Age
- 18-75 years old
- Sex
- Men and women can join.
- Disease stage
- Non-small cell lung cancer, stage I-II (TNM), confirmed by tissue examination. Cohort 1: multiple or single primary lung cancer by clinical criteria. Cohort 2: one or more lung nodules with cystic airspaces on CT.
- Earlier treatment
- People who had chemotherapy, radiotherapy or targeted therapy (such as monoclonal antibodies or small-molecule tyrosine kinase inhibitors) before joining cannot join.
Main reasons for not taking part
- Another cancer in the past or at the same time
- Chemotherapy, radiotherapy or targeted therapy before joining
- Refusing to take part in the study
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Male or female patients:18-75 years old
- ECOG score:0-1
- Histopathologically confirmed TNM stage I-II NSCLC
- Considered multiple or solitary primary lung cancer by clinical criteria (Martini-Melamed criteria and ACCP criteria)
- Good compliance, family members agree to cooperate to receive survival follow-up
- Understand and voluntarily sign the informed consent
- Male or female patients:18-75 years old
- ECOG score:0-1
- Histopathologically confirmed TNM stage I-II NSCLC
- CT findings show solitary or multiple nodules with cystic airspaces
Who cannot take part
- A history of previous or co-existing malignant tumors
- Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment
- A history of previous or co-existing malignant tumors
- Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment
- Refusal to participate in the study; Cohort 2: Multi-omics study of lung cancer associated with cystic airspaces
- Refusal to participate in the study
Other criteria
- Cohort 1: Multi-omics study in early-stage synchronous multiple primary lung cancer
Where in China
- The Second Xiangya Hospital of Central South UniversityChangsha, ChinaContact: Ping JiangTaking people
About the trial
What the trial wants to find out
The goal of this observational study is to investigate the multi-omics characterization early-stage lung cancer exhibiting distinct phenotypes including lung cancer associated with cystic airspaces, multiple primary lung cancers, and so on. The main questions it aims to answer are:
Read full original descriptionShow less
* What are the differences in pathogenesis of non-small cell lung cancer with different phenotypes explored by multi-omics? * Whether differential genes lead to potential prognostic models and therapeutic targets? Participants will be followed up after surgery to answer prognosis: whether they have recurred, and the time to recurrence.
The group in the trial
- Non-small cell lung cancer
Early-stage lung cancer exhibiting distinct phenotypes including lung cancer associated with cystic airspaces, multiple primary lung cancers, and so on.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Comprehensive Multi-Omics Analysis of Early-Stage Lung Cancer Exhibiting Distinct Phenotypes
- Plain-language title
- Studying Early Lung Cancer Types Using Multi-Omics AnalysisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 7 July 2026